Champlain Investment Partners LLC Sells 197,570 Shares of DexCom, Inc. (NASDAQ:DXCM)

Champlain Investment Partners LLC decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,015,713 shares of the medical device company's stock after selling 197,570 shares during the quarter. Champlain Investment Partners LLC owned about 0.52% of DexCom worth $156,762,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in DXCM. Versant Capital Management Inc acquired a new stake in DexCom in the fourth quarter valued at $25,000. Private Trust Co. NA lifted its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC increased its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $38,000. Institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock valued at $8,044,178 over the last ninety days. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on DXCM shares. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Finally, Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

DexCom Price Performance

DXCM stock traded up $0.51 during mid-day trading on Tuesday, hitting $66.62. The stock had a trading volume of 1,311,572 shares, compared to its average volume of 4,210,274. The firm has a fifty day simple moving average of $74.62 and a 200 day simple moving average of $76.74. The firm has a market capitalization of $26.12 billion, a P/E ratio of 46.52, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $139.24.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.